SCHEMBL104947

SCHEMBL104947

CC(C)Oc1cccc(F)c1N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 1/20 0.46
IRAK4 Q9NWZ3 2/20 0.42
ALDH1A1 P00352 3/20 0.40
GAA P10253 1/20 0.40
ALOX5AP P20292 1/20 0.40
FEN1 P39748 1/20 0.40
HTR1A P08908 2/20 0.40
HTR7 P34969 2/20 0.40
HTR1D P28221 1/20 0.40
HTR2C P28335 1/20 0.40
HTR5A P47898 1/20 0.40
TLR8 Q9NR97 1/20 0.39
KCNN4 O15554 1/20 0.38
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA7 P43166 1/20 0.37
CA9 Q16790 1/20 0.37
ACHE P22303 1/20 0.36
NPSR1 Q6W5P4 1/20 0.35
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2773853 0.85 MCHR1 (0.53) MCHR1IRAK4ALDH1A1HTR1AHTR7
SCHEMBL11916618 0.79 SLC6A2 (0.43) MCHR1IRAK4ALDH1A1GAAHTR1A
SCHEMBL2841640 0.79 MCHR1 (0.49) MCHR1IRAK4ALDH1A1GAAHTR1A
SCHEMBL17070600 0.79 ALDH1A1 (0.53) IRAK4ALDH1A1GAAALOX5APFEN1
SCHEMBL104729 0.79 ALDH1A1 (0.53) IRAK4ALDH1A1GAAALOX5APFEN1
SCHEMBL16606250 0.78 MCHR1 (0.40) MCHR1IRAK4ALDH1A1GAAALOX5AP
SCHEMBL13263183 0.78 KCNN4 (0.41) MCHR1IRAK4ALDH1A1GAAALOX5AP
SCHEMBL5409325 0.78 MCHR1 (0.47) MCHR1IRAK4ALDH1A1HTR1AHTR7
SCHEMBL108534 0.77 TDP1 (0.48) MCHR1ALDH1A1GAACA1CA2
SCHEMBL17887314 0.76 MCHR1 (0.46) MCHR1IRAK4ALDH1A1HTR1AHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3237385-B1 MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER US HEALTH (US) 2021-11-24 EP disclosed
US-10703746-B2 Mutant IDH1 inhibitors useful for treating cancer THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2020-07-07 US disclosed
US-20190071434-A1 MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER THE USA AS REPRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES (US) 2019-03-07 US disclosed
EP-3129358-A1 DIAMINOTRIAZINE DERIVATIVES AS HERBICIDES BASF SE (DE) 2017-02-15 EP disclosed
US-20170029383-A1 Diaminotriazine Derivatives as Herbicides BASF SE (DE) 2017-02-02 US disclosed
CN-106164058-A Diaminourea pyrrolotriazine derivatives as herbicide 巴斯夫欧洲公司 2016-11-23 CN disclosed
WO-2016106331-A1 MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER THE UNITED STATES OF AMERICA (US) 2016-06-30 WO disclosed
WO-2015155271-A1 DIAMINOTRIAZINE DERIVATIVES AS HERBICIDES BASF SE (DE) 2015-10-15 WO disclosed
US-20120059162-A1 FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION ONCOTHERAPY SCIENCE, INC. (JP) 2012-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059162-A1 FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION NR0B1, GRK7, NR5A2 MCHR1 1652/4885IRAK4 1082/4885ALDH1A1 3128/4885
US-20170029383-A1 Diaminotriazine Derivatives as Herbicides DDT, CBR3, HDHD5 MCHR1 2093/4885IRAK4 4405/4885ALDH1A1 348/4885
US-20190071434-A1 MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER IDH1, IDH3B, IDH3A MCHR1 4586/4885IRAK4 3380/4885ALDH1A1 417/4885
US-10703746-B2 Mutant IDH1 inhibitors useful for treating cancer IDH1, IDH3B, IDH3A MCHR1 4586/4885IRAK4 3380/4885ALDH1A1 417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.